financetom
Business
financetom
/
Business
/
Stellantis CEO Says US Tariff Environment 'Getting Clearer,' Sees Cash Generation as Urgent Objective
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stellantis CEO Says US Tariff Environment 'Getting Clearer,' Sees Cash Generation as Urgent Objective
Sep 12, 2025 5:34 AM

08:05 AM EDT, 09/12/2025 (MT Newswires) -- Stellantis ( STLA ) Chief Executive Antonio Filosa said Thursday the US tariff environment is "getting clearer" though not fully defined, and that the company is "ready to act."

Speaking in a fireside talk during the Kepler Cheuvreux Autumn Conference, Filosa said Stellantis ( STLA ) is engaged in a "very productive exchange of ideas" with President Donald Trump's administration to "create the final scenario." He said the company's most urgent objective is to "turn the corner on cash generation" and grow the revenue line.

In 2024, over 40% of the 1.2 million cars Stellantis ( STLA ) sold in the US were imports, mostly from Mexico and Canada, where Trump imposed 25% tariffs, Reuters reported Thursday.

Filosa also said the inventories are now at "very healthy" levels, with 2024 models cleared. In late July, Stellantis ( STLA ) reported 1.2 million units of total inventories, including 298,000 units of company inventory as of June 30.

Filosa also said a new RAM truck for the North American market is expected in 2027.

Shares of the automaker were down 2.9% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
HAFNIA LIMITED: Hafnia Completes Acquisition of 13.97% of TORM
HAFNIA LIMITED: Hafnia Completes Acquisition of 13.97% of TORM
Mar 10, 2026
SINGAPORE--(BUSINESS WIRE)-- With reference to the stock exchange announcement of 18 December 2025, in which Hafnia Limited ( HAFN ) announced that all conditions precedent for completion of the share purchase agreement (the “Share Purchase Agreement”) entered into with Oaktree Capital Management, L.P. and its affiliates (together, Oaktree), have been satisfied, Hafnia ( HAFN ) is pleased to announce that...
Primaris REIT Says Completed $154M Strategic Disposition and Provided Financing Update
Primaris REIT Says Completed $154M Strategic Disposition and Provided Financing Update
Mar 10, 2026
05:42 PM EST, 12/22/2025 (MT Newswires) -- Primaris Real Estate Investment Trust (PMZ-UN.TO) after trade Monday said it completed the sale of Northland Village and Northland Professional Centre in Calgary for $154 million to a Canadian institutional investor on Dec. 19. Northland Village, a recently redeveloped open-air centre in northwest Calgary, is anchored by Walmart, Winners, Best Buy, GoodLife and...
Synopsys Insider Sold Shares Worth $1,685,036, According to a Recent SEC Filing
Synopsys Insider Sold Shares Worth $1,685,036, According to a Recent SEC Filing
Mar 10, 2026
05:42 PM EST, 12/22/2025 (MT Newswires) -- Shelagh Glaser, CFO, on December 19, 2025, sold 3,657 shares in Synopsys ( SNPS ) for $1,685,036. Following the Form 4 filing with the SEC, Glaser has control over a total of 17,842 common shares of the company, with 17,842 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/883241/000186550425000010/xslF345X05/edgardoc.xml ...
Amneal Reports FDA Approval of Denosumab Biosimilars
Amneal Reports FDA Approval of Denosumab Biosimilars
Mar 10, 2026
04:35 PM EST, 12/22/2025 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) and partner mAbxience said late Monday that the US Food and Drug Administration has approved their denosumab biosimilars, Boncresa and Oziltus. Boncresa is a biosimilar referencing Prolia, and Oziltus is a biosimilar referencing XGEVA, they said. Under the partnership, mAbxience develops and manufactures the drugs, while Amneal holds...
Copyright 2023-2026 - www.financetom.com All Rights Reserved